Literature DB >> 25246592

Cell fate regulation by gelsolin in human gynecologic cancers.

Mohammad R Abedini1, Pei-Wen Wang2, Yu-Fang Huang3, Mingju Cao4, Cheng-Yang Chou5, Dar-Bin Shieh6, Benjamin K Tsang7.   

Abstract

Chemoresistance is a major hurdle in cancer treatment. Down-regulation of apoptosis pathways is one of the key determinants for chemoresistance. Here, we report higher gelsolin (GSN) levels in chemoresistant gynecological cancer cells compared with their sensitive counterparts. cis-Diammine dichloroplatinium (II) (CDDP)-induced GSN down-regulation is associated with its cleavage and apoptosis. Although the C-terminal GSN fragment (C-GSN) sensitized chemoresistant cells to CDDP, intact GSN and its N-terminal fragment (N-GSN) attenuated this response. GSN silencing also facilitated CDDP-induced apoptosis in chemoresistant cells. In contrast, intact GSN (I-GSN) was prosurvival in the presence of CDDP through a FLICE-like inhibitory protein (FLIP)-Itch interaction. This interaction was colocalized in the perinuclear region that could be dissociated by CDDP in sensitive cells, thereby inducing FLIP ubiquitination and degradation, followed by apoptosis. In resistant cells, GSN was highly expressed and CDDP failed to abolish the I-GSN-FLIP-Itch interaction, resulting in the dysregulation of the downstream responses. In addition, we investigated the association between GSN expression in ovarian serous adenocarcinoma and progression free survival and overall survival, as well as clinical prognosis. GSN overexpression was significantly associated with more aggressive behavior and more cancer deaths and supported our hypothesis that high GSN expression confers chemoresistance in cancer cells by altering the GSN-FLIP-Itch interaction. These findings are in agreement with the notion that GSN plays an important role in the regulation of gynecological cell fate as reflected in dysregulation in chemosensitivity.

Entities:  

Keywords:  cervical cancer; ovarian cancer

Mesh:

Substances:

Year:  2014        PMID: 25246592      PMCID: PMC4209992          DOI: 10.1073/pnas.1401166111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Tissue expression of gelsolin in oral carcinogenesis progression and its clinicopathological implications.

Authors:  Dar-Bin Shieh; I-Wen Chen; Tsai-Yin Wei; Chuin-Yi Shao; Hsin-Ju Chang; Ching-Hung Chung; Tung-Yiu Wong; Ying-Tai Jin
Journal:  Oral Oncol       Date:  2006-06-06       Impact factor: 5.337

Review 2.  Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.

Authors:  J Sehouli; V Alfaro; A González-Martín
Journal:  Ann Oncol       Date:  2011-07-06       Impact factor: 32.976

Review 3.  Optimal treatment for relapsing ovarian cancer.

Authors:  J A Ledermann; R S Kristeleit
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

4.  Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.

Authors:  Maurie Markman; P Y Liu; James Moon; Bradley J Monk; Larry Copeland; Sharon Wilczynski; David Alberts
Journal:  Gynecol Oncol       Date:  2009-05-17       Impact factor: 5.482

5.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

Authors:  Noriyuki Katsumata; Makoto Yasuda; Fumiaki Takahashi; Seiji Isonishi; Toshiko Jobo; Daisuke Aoki; Hiroshi Tsuda; Toru Sugiyama; Shoji Kodama; Eizo Kimura; Kazunori Ochiai; Kiichiro Noda
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

6.  Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.

Authors:  Michael Fraser; Tao Bai; Benjamin K Tsang
Journal:  Int J Cancer       Date:  2008-02-01       Impact factor: 7.396

7.  Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.

Authors:  M R Abedini; E J Muller; R Bergeron; D A Gray; B K Tsang
Journal:  Oncogene       Date:  2009-10-05       Impact factor: 9.867

8.  Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells.

Authors:  Mohammad R Abedini; Emilie J Muller; Jan Brun; Richard Bergeron; Douglas A Gray; Benjamin K Tsang
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

9.  Gelsolin, but not its cleavage, is required for TNF-induced ROS generation and apoptosis in MCF-7 cells.

Authors:  Qinxi Li; Zhiyun Ye; Jun Wen; Lin Ma; Ying He; Guili Lian; Zhen Wang; Luyao Wei; Di Wu; Bin Jiang
Journal:  Biochem Biophys Res Commun       Date:  2009-05-22       Impact factor: 3.575

Review 10.  Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer.

Authors:  Bradley J Monk; Heather Dalton; John H Farley; Dana M Chase; Ivor Benjamin
Journal:  Crit Rev Oncol Hematol       Date:  2012-11-06       Impact factor: 6.312

View more
  23 in total

1.  Regulation of autoimmune disease by the E3 ubiquitin ligase Itch.

Authors:  Emily K Moser; Paula M Oliver
Journal:  Cell Immunol       Date:  2019-04-05       Impact factor: 4.868

2.  Crocin and Metformin suppress metastatic breast cancer progression via VEGF and MMP9 downregulations: in vitro and in vivo studies.

Authors:  Ali Farahi; Mohammad Reza Abedini; Hossein Javdani; Laleh Arzi; Elham Chamani; Ramin Farhoudi; Nazanin Talebloo; Reyhane Hoshyar
Journal:  Mol Cell Biochem       Date:  2021-04-30       Impact factor: 3.396

3.  Identifying a cervical cancer survival signature based on mRNA expression and genome-wide copy number variations.

Authors:  Nan Li; Kai Yu; Zhong Lin; Dingyuan Zeng
Journal:  Exp Biol Med (Maywood)       Date:  2021-10-21

4.  Gelsolin Promotes Radioresistance in Non-Small Cell Lung Cancer Cells Through Activation of Phosphoinositide 3-Kinase/Akt Signaling.

Authors:  Ru-Sen Zhao; Wei Wang; Jun-Ping Li; Chun-Mei Liu; Liya He
Journal:  Technol Cancer Res Treat       Date:  2016-04-27

Review 5.  "Ziziphus jujuba": A red fruit with promising anticancer activities.

Authors:  Zoya Tahergorabi; Mohammad Reza Abedini; Moodi Mitra; Mohammad Hassanpour Fard; Hossein Beydokhti
Journal:  Pharmacogn Rev       Date:  2015 Jul-Dec

Review 6.  FLIP the Switch: Regulation of Apoptosis and Necroptosis by cFLIP.

Authors:  Yuichi Tsuchiya; Osamu Nakabayashi; Hiroyasu Nakano
Journal:  Int J Mol Sci       Date:  2015-12-18       Impact factor: 5.923

7.  Involvement of gelsolin in TGF-beta 1 induced epithelial to mesenchymal transition in breast cancer cells.

Authors:  Zhi-Yuan Chen; Pei-Wen Wang; Dar-Bin Shieh; Kuan-Ying Chiu; Ying-Ming Liou
Journal:  J Biomed Sci       Date:  2015-10-20       Impact factor: 8.410

8.  Transcriptome analysis discloses dysregulated genes in normal appearing tumor-adjacent thyroid tissues from patients with papillary thyroid carcinoma.

Authors:  Huiling He; Sandya Liyanarachchi; Wei Li; Daniel F Comiskey; Pearlly Yan; Ralf Bundschuh; Altan M Turkoglu; Pamela Brock; Matthew D Ringel; Albert de la Chapelle
Journal:  Sci Rep       Date:  2021-07-08       Impact factor: 4.379

9.  Anti-proliferative and apoptotic effects of Ziziphus Jujube on cervical and breast cancer cells.

Authors:  Mohammad Reza Abedini; Nafiseh Erfanian; Habibollah Nazem; Sara Jamali; Reyhane Hoshyar
Journal:  Avicenna J Phytomed       Date:  2016 Mar-Apr

10.  Secreted gelsolin desensitizes and induces apoptosis of infiltrated lymphocytes in prostate cancer.

Authors:  Chun-Chi Chen; Shiow-Her Chiou; Cheng-Lin Yang; Kuan-Chih Chow; Tze-Yi Lin; Hui-Wen Chang; Weir-Chiang You; Hisu-Wen Huang; Chien-Min Chen; Nien-Cheng Chen; Fen-Pi Chou; Ming-Chih Chou
Journal:  Oncotarget       Date:  2017-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.